Biodesix Q4 revenue $14.7M (+53% YoY); guides FY2024 revenue $65-$68M

BIODESIX INC

Full-year 2023 revenue $49.1M, +28% YoY; Lung Diagnostic test volume up 65%.
Q4 gross margin 77% vs 66% a year ago; net loss improved 55% to $9.1M.
FY2023 Adjusted EBITDA loss $32.7M, improved 24% YoY.
Cash $26.3M at Dec 31, 2023; drew $10M second tranche from Perceptive term loan.
FY2024 revenue guidance $65-$68M, representing 32%-39% YoY growth.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIODESIX INC reported the fourth quarter and year ended December 31, 2023 results: revenue $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively, net income Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively. Guidance reaffirmed.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively
Net income: Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0000950170-24-023509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.